New Meds and Tech

Brief Therapeutic Update from PES Drugs and Therapeutics Committee Sogroya® (somapactian) Once weekly Sogroya® (somapacitan-beco, Novo Nordisk) was approved by the United States Food and Drug…

Brief Therapeutic Update from PES Drugs and Therapeutics Committee The MiniMed™780G System The MiniMed 780G System from Medtronic was approved by the US Food and Drug…

Dexcom G7   In December 2022, the Dexcom G7 continuous glucose monitor system was cleared by the FDA for use in people age 2 and older…

Wegovy® (semaglutide) once weekly injection is a glucagon-like peptide 1 receptor agonist (GLP1-RA) approved by the FDA in June, 2021 for weight management in adults. Wegovy…

Difficulty filling prescriptions for diazoxide have been reported intermittently. Teva Pharmaceuticals reports that Proglycem® Oral Suspension 50 mg/mL 30 mL (NDC 00575-6200-30) is currently available. Providers…

On November 17, 2022, the FDA announced the approval of TZIELDTM (teplizumab-mzwv), which is a CD-3 directed monoclonal antibody. This first-in-class therapy is intended to delay…

New Meds and Tech from PES Drugs and Therapeutics committee In June 2022, the Food and Drug Administration (FDA) approved a supplemental indication for Qsymia (phentermine…

New Meds and Tech from PES Drugs and Therapeutics committee The FreeStyle Libre 3 is the third generation of Abbot Laboratories’ continuous glucose monitoring system intended…

New Meds and Tech from PES Drugs and Therapeutics committee The Omnipod 5 (Insulet Inc) is a hybrid closed-loop system approved by the FDA on January…

New Meds and Tech from PES Drugs and Therapeutics committee PES Drug Alert – GnRH agonists On July 1, 2022 the Food and Drug Administration (FDA)…